Mark E. Fraley

1.9k citations

44 papers · 1.7k · h-index 25

Impact in

Organic Chemistry top 2%
- Synthesis and biological activity
- Catalytic Cross-Coupling Reactions
- Asymmetric Synthesis and Catalysis
Cell Biology top 5%
- Microtubule and mitosis dynamics

Papers in

Organic Chemistry 14
- Synthesis and biological activity 13
Psychiatry and Mental health 4
- Migraine and Headache Studies 4

Co-authors: Norma J. Tom (4 shared papers)Andrew G. Myers (4 shared papers)Scott B. Cohen (3 shared papers)David J. Madar (3 shared papers)George D. Hartman (13 shared papers)Robert S. Rubino (3 shared papers)Kenneth A. Thomas (7 shared papers)Kathleen E. Coll (7 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (20 papers)ACS Medicinal Chemistry Letters (3 papers)Journal of the American Chemical Society (3 papers)Cancer Research (2 papers)Expert Opinion on Therapeutic Patents (2 papers)
Partner nations: United States

In The Last Decade

Mark E. Fraley

44 papers receiving 1.6k citations

Peers

Countries citing papers authored by Mark E. Fraley

Since Specialization

Citations

This map shows the geographic impact of Mark E. Fraley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Fraley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Fraley more than expected).

Fields of papers citing papers by Mark E. Fraley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Fraley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Fraley. The network helps show where Mark E. Fraley may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark E. Fraley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Fraley Line = papers co-authored together Mark E. Fraley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Convergent Synthetic Route to (+)-Dynemicin A and Analogs of Wide Structural Variability Journal of the American Chemical Society ·Andrew G. Myers, Norma J. Tom, Mark E. Fraley, Scott B. Cohen, David J. Madar	1997	175
2	Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer Journal of Medicinal Chemistry ·Christopher D. Cox, P.J. Coleman, Michael J. Breslin, David B. Whitman, R. M. Garbaccio, Mark E. Fraley, Carolyn A. Buser, Eileen S. Walsh	2008	147
3	Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, William F. Hoffman, Robert S. Rubino, Randall W. Hungate, Andrew J. Tebben, Ruth Z. Rutledge, Rosemary C. McFall, William R. Huckle	2002	108
4	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, Robert S. Rubino, William F. Hoffman, Scott R. Hambaugh, Kenneth L. Arrington, Randall W. Hungate, Mark T. Bilodeau, Andrew J. Tebben	2002	80
5	Synthesis of (+)-dynemicin A and analogs of wide structural variability: establishment of the absolute configuration of natural dynemicin A Chemistry & Biology ·Andrew G. Myers, Mark E. Fraley, Norma J. Tom, Scott B. Cohen, David J. Madar	1995	75
6	Development of thioquinazolinones, allosteric Chk1 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Antonella Converso, Timothy J. Hartingh, R. M. Garbaccio, Edward S. Tasber, Keith W. Rickert, Mark E. Fraley, Youwei Yan, Constantine Kreatsoulas	2008	69
7	Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor Journal of Pharmacology and Experimental Therapeutics ·Eric L. Moore, Mark E. Fraley, Ian M. Bell, Christopher S. Burgey, Rebecca B. White, Chi‐Chung Li, Christopher P. Regan, Andrew Danziger	2020	62
8	Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia ChemMedChem ·Anthony J. Roecker, Swati P. Mercer, John D. Schreier, Christopher D. Cox, Mark E. Fraley, Justin T. Steen, Wei Lemaire, Joseph G. Bruno	2013	61
9	Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, R. M. Garbaccio, Kenneth L. Arrington, William F. Hoffman, Edward S. Tasber, P.J. Coleman, Carolyn A. Buser, Eileen S. Walsh	2006	58
10	An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis Molecular and Cellular Biology ·Weikang Tao, Victoria J. South, Ronald E. Diehl, Joseph P. Davide, Laura Sepp‐Lorenzino, Mark E. Fraley, Kenneth L. Arrington, Robert B. Lobell	2006	52
11	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, Kenneth L. Arrington, Carolyn A. Buser, Patrice A. Ciecko, Kathleen E. Coll, Christine Fernandes, George D. Hartman, William F. Hoffman	2003	49
12	Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorganic & Medicinal Chemistry Letters ·Christopher D. Cox, Michael J. Breslin, David B. Whitman, P.J. Coleman, R. M. Garbaccio, Mark E. Fraley, Matthew M. Zrada, Carolyn A. Buser	2007	49
13	Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents Expert Opinion on Investigational Drugs ·George D. Hartman, Mark E. Fraley, Mark T. Bilodeau	2002	46
14	3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6 Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, Justin T. Steen, Edward J. Brnardic, Kenneth L. Arrington, Keith L. Spencer, Barbara Hanney, Yuntae Kim, George D. Hartman	2006	45
15	Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility Bioorganic & Medicinal Chemistry Letters ·R. M. Garbaccio, Mark E. Fraley, Edward S. Tasber, Christy M. Olson, William F. Hoffman, Kenneth L. Arrington, Maricel Torrent, Carolyn A. Buser	2006	41
16	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR Bioorganic & Medicinal Chemistry Letters ·Zhicai Wu, Mark E. Fraley, Mark T. Bilodeau, Mildred L. Kaufman, Edward S. Tasber, Adrienne E. Balitza, George D. Hartman, Kathleen E. Coll	2004	39
17	Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Edward J. Brnardic, R. M. Garbaccio, Mark E. Fraley, Edward S. Tasber, Justin T. Steen, Kenneth L. Arrington, Vadim Dudkin, George D. Hartman	2007	39
18	3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts Bioorganic & Medicinal Chemistry Letters ·Edward J. Brnardic, Mark E. Fraley, R. M. Garbaccio, Mark E. Layton, John M. Sanders, Chris Culberson, Marlene A. Jacobson, Brian C. Magliaro	2010	39
19	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert Opinion on Therapeutic Patents ·Mark E. Fraley	2009	37
20	Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Shaei Huang, R. M. Garbaccio, Mark E. Fraley, Justin T. Steen, Constantine Kreatsoulas, George D. Hartman, Steven M. Stirdivant, Bob A. Drakas	2006	35

About Mark E. Fraley

Mark E. Fraley is a scholar working on Organic Chemistry, Psychiatry and Mental health, Cell Biology, Molecular Biology and Pharmacology, having authored 44 papers that have together received 1.7k indexed citations. Recurring topics across this work include Synthesis and biological activity (13 papers), Migraine and Headache Studies (4 papers), Microtubule and mitosis dynamics (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Cell death mechanisms and regulation (1 paper), DNA and Nucleic Acid Chemistry (1 paper) and Lysosomal Storage Disorders Research (1 paper). The work is most often cited by research in Organic Chemistry (499 citations), Cell Biology (116 citations), Computational Theory and Mathematics (129 citations), Pharmaceutical Science (47 citations) and Psychiatry and Mental health (81 citations). Mark E. Fraley has collaborated with scholars based in United States. Frequent co-authors include Norma J. Tom, Andrew G. Myers, Scott B. Cohen, David J. Madar, George D. Hartman, Robert S. Rubino, Kenneth A. Thomas, Kathleen E. Coll, William F. Hoffman and Mark T. Bilodeau. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters, Journal of the American Chemical Society, Cancer Research and Expert Opinion on Therapeutic Patents.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark E. Fraley

Impact in

Papers in i

In The Last Decade

Mark E. Fraley

Peers

Countries citing papers authored by Mark E. Fraley

Fields of papers citing papers by Mark E. Fraley

All Works

About Mark E. Fraley

Explore authors with similar magnitude of impact

Papers in